KNTE · Kinnate Biopharma
Acquired Company
XOMA completed its acquisition of Kinnate Biopharma Inc. on April 3, 2024 via a tender offer to acquire all outstanding KNTE shares for $2.5879 per share in cash, plus one non-tradeable contingent value right per share.
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$2.65
Open
$2.65
Volume
N/A
Day Range
$2.65 - $2.65
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
0.16%
Institutional Own.
82.58%
Qtr Updated
Mar 31st 2024
